What is your preferred first-line therapy for a patient with standard risk multiple myeloma?  

Has the recent data presented at ASH affected your choice of regimen?

Would your choice differ between transplant-eligible and transplant-ineligible patients?



Answer from: Medical Oncologist at Community Practice